The filing is a routine notice of an upcoming earnings webcast. No actionable trading signal is present. Monitor the webcast on August 26-27 for the actual FY2026 financial results and any material updates on pipeline or commercial progress.
Drugs in focus
MESO drug pipeline →rexlemestrocel-L
▲ Bullish Named in this 6-K- Impact
- Phase
- Phase 3 / Filed BLA
- Time to market
- LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
- Next catalyst
- None dated
What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 24 $16.64entry
- T+1 · 3mo ago +3.31%α +2.99% · $17.19
- T+5 · 3mo ago +0.72%α +0.25% · $16.76
- T+20 · 8w ago −4.33%α −5.64% · $15.92
- T+59 · todayOpen
- T+60 · in 4h Pending
Price Chart
How similar events traded
Executive Summary
Mesoblast filed a 6-K announcing a webcast to discuss operational highlights and financial results for the full year ended June 30, 2026. The filing is a routine notice of an upcoming earnings event and contains no actual financial data or material corporate developments. The webcast is scheduled for August 26-27, 2026.
Key Facts
- Mesoblast will host a webcast on August 26-27, 2026, to discuss FY2026 financial results and operational highlights.
- The filing is a notice of an upcoming event and contains no financial figures or material business updates.
- Ryoncil (remestemcel-L) is the first FDA-approved MSC therapy for SR-aGvHD in pediatric patients.
Financial Impact
No financial data provided in the filing.
Risk Factors
- No financial data or guidance was provided in this filing, limiting its immediate informational value.
- The filing does not disclose any material risks or changes to the company's outlook.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000076 |
| Document: 0001345099-26-000076-index-headers.html | 0001345099-26-000076 |
| Document: 0001345099-26-000076-index.html | 0001345099-26-000076 |
| Document: 0001345099-26-000076.txt | 0001345099-26-000076 |
Track record
25 reports on MESO
7 of 15 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 10 of 15 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
- Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
- Oct 29, 202618d ago 6-K Bullish 6/10 No price data
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
- Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
- Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
- Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
- Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
- Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers